P D Miller

Summary

Publications

  1. ncbi request reprint Clinical use of teriparatide in the real world: initial insights
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, 80227, USA
    Endocr Pract 10:139-48. 2004
  2. ncbi request reprint Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy
    Paul D Miller
    Colorado Center for Bone Research, Lakewood 80227, USA
    Clin Ther 27:361-76. 2005
  3. ncbi request reprint Should low bone mass be treated?
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    Int J Fertil Womens Med 50:83-7. 2005
  4. ncbi request reprint Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    P D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO, USA
    Osteoporos Int 18:59-68. 2007
  5. doi request reprint Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies
    P D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Blvd, Lakewood, CO, 80227, USA
    Osteoporos Int 25:349-57. 2014
  6. pmc Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:227-35. 2013
  7. doi request reprint Unrecognized and unappreciated secondary causes of osteoporosis
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Lakewood, CO 80227, USA
    Endocrinol Metab Clin North Am 41:613-28. 2012
  8. doi request reprint Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
    P D Miller
    Colorado Center for Bone Research, Lakewood, CO, USA
    Osteoporos Int 23:1747-56. 2012
  9. doi request reprint Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study
    Paul D Miller
    Colorado Center for Bone Research, PC, Lakewood, CO 80227, USA
    Bone 49:1317-22. 2011
  10. doi request reprint Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Ste 250, Lakewood, CO 80227, USA
    Bone 43:222-9. 2008

Collaborators

Detail Information

Publications88

  1. ncbi request reprint Clinical use of teriparatide in the real world: initial insights
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, 80227, USA
    Endocr Pract 10:139-48. 2004
    ..To summarize expert opinion regarding clinical application of the recently introduced anabolic agent teriparatide [human parathyroid hormone (1-34)] in treatment of postmenopausal osteoporosis in women, and osteoporosis in men...
  2. ncbi request reprint Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy
    Paul D Miller
    Colorado Center for Bone Research, Lakewood 80227, USA
    Clin Ther 27:361-76. 2005
    ....
  3. ncbi request reprint Should low bone mass be treated?
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    Int J Fertil Womens Med 50:83-7. 2005
    ..Algorithms are being developed to enhance risk stratification to facilitate decisions when to treat in the osteopenic population. Evidence exists that osteoporosis agents can reduce fracture risk in the osteopenic population...
  4. ncbi request reprint Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    P D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO, USA
    Osteoporos Int 18:59-68. 2007
    ..The prevalence of both osteoporosis and renal impairment increases with age...
  5. doi request reprint Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies
    P D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Blvd, Lakewood, CO, 80227, USA
    Osteoporos Int 25:349-57. 2014
    ..This analysis, in which fractures were reported as safety events, showed that long-term use of ibandronate was associated with low fracture rates over 5 years of treatment...
  6. pmc Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:227-35. 2013
    ..Denosumab treatment was well tolerated throughout the 8-year study...
  7. doi request reprint Unrecognized and unappreciated secondary causes of osteoporosis
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Lakewood, CO 80227, USA
    Endocrinol Metab Clin North Am 41:613-28. 2012
    ..Through targeted laboratory tests, many secondary causes of osteoporosis can be identified...
  8. doi request reprint Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
    P D Miller
    Colorado Center for Bone Research, Lakewood, CO, USA
    Osteoporos Int 23:1747-56. 2012
    ..4%). Long-term monthly ibandronate is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis...
  9. doi request reprint Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study
    Paul D Miller
    Colorado Center for Bone Research, PC, Lakewood, CO 80227, USA
    Bone 49:1317-22. 2011
    ....
  10. doi request reprint Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Ste 250, Lakewood, CO 80227, USA
    Bone 43:222-9. 2008
    ..We assessed the long-term efficacy and safety of denosumab, and the effects of discontinuing and restarting denosumab treatment in postmenopausal women with low bone mass...
  11. ncbi request reprint Guidelines for the diagnosis of osteoporosis: T-scores vs fractures
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood, CO, USA
    Rev Endocr Metab Disord 7:75-89. 2006
    ..The field of osteoporosis has grown with the use of DXA and will continue to embrace this technology as other technologies to measure fracture risk become applied in clinical practice...
  12. ncbi request reprint Monitoring osteoporosis therapies
    Paul D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Boulevard, Suite 250, Lakewood, CO 80227, USA
    Curr Osteoporos Rep 5:38-43. 2007
    ..Integrating these markers enhances overall patient care. The surrogate markers help the clinician to achieve the goal of managing PMO; attempting to manage PMO without markers reduces the clinical management to guesswork...
  13. ncbi request reprint Is there a role for bisphosphonates in chronic kidney disease?
    Paul D Miller
    Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Semin Dial 20:186-90. 2007
    ..More data are needed to define the risks and benefits of BPs in patients with stage 5 CKD...
  14. ncbi request reprint Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
    Paul D Miller
    FACP, Colorado Center for Bone Research, 3190 South Wadsworth, Suite 250, Lakewood, Colorado 80227, USA
    J Clin Endocrinol Metab 92:3535-41. 2007
    ..Teriparatide (TPTD) [recombinant human PTH(1-34)] given sc once daily transiently increases serum calcium concentrations at 4-6 h after dosing, but its effects on urinary calcium excretion are less well studied...
  15. doi request reprint What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?
    P D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Lakewood, CO 80227, USA
    Osteoporos Int 21:1793-802. 2010
    ..Because no single agent is appropriate for all patients, treatment decisions should be made on an individual basis, taking into account the relative benefits and risks in different patient populations...
  16. ncbi request reprint Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials
    Paul D Miller
    University of Colorado Health Science Center, Colorado Center for Bone Research, Lakewood, USA
    J Bone Miner Res 20:2105-15. 2005
    ..We studied the influence of renal function on the safety and efficacy of risedronate 5 mg daily in osteoporotic women. Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment...
  17. ncbi request reprint Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction
    Paul D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Blvd, Lakewood, CO 80227, USA
    Curr Osteoporos Rep 3:103-10. 2005
    ..In this regard, changes in BMD and BTM are complimentary in their application to patient management...
  18. ncbi request reprint Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, 80227, USA
    J Rheumatol 32:1556-62. 2005
    ..To compare the effects on back pain of teriparatide versus alendronate, we analyzed the reporting of back pain in a head to head comparator trial and a followup study...
  19. ncbi request reprint Treatment of osteoporosis in chronic kidney disease and end-stage renal disease
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth 250, Lakewood, CO 80227, USA
    Curr Osteoporos Rep 3:5-12. 2005
    ....
  20. ncbi request reprint Pitfalls in bone mineral density measurements
    Paul D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Blvd, Lakewood, CO 80227, USA
    Curr Osteoporos Rep 2:59-64. 2004
    ..Proper education and training in the use of BMD technologies provides the means of achieving the great intent that BMD measurements are capable of providing...
  21. ncbi request reprint Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, CO 80227, USA
    Curr Med Res Opin 24:107-19. 2008
    ....
  22. ncbi request reprint Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    Curr Med Res Opin 24:207-13. 2008
    ..To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg...
  23. ncbi request reprint Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Bone Miner Res 23:525-35. 2008
    ..Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD...
  24. doi request reprint Vitamin D, calcium, and cardiovascular mortality: a perspective from a plenary lecture given at the annual meeting of the American Association of Clinical Endocrinologists
    Paul D Miller
    Colorado Center for Bone Research, University of Colorado Health Sciences Center, Lakewood, Colorado, USA
    Endocr Pract 17:798-806. 2011
    ..To examine data showing associations between serum 25-hydroxyvitamin D levels and calcium intake and cardiovascular mortality...
  25. doi request reprint The kidney and bisphosphonates
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood, 80227, USA
    Bone 49:77-81. 2011
    ..Bisphosphonates are safe and effective for the management of osteoporosis when used in the right dose and in the right patient population for the right duration...
  26. doi request reprint Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Ste 250, Lakewood, Colorado 80227, USA
    J Clin Endocrinol Metab 96:394-402. 2011
    ..This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass...
  27. doi request reprint Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, CO 80227, USA
    Calcif Tissue Int 87:305-13. 2010
    ..This analysis suggests that ibandronate-induced BMD gain in postmenopausal osteoporotic women is associated with vertebral fracture risk reduction...
  28. doi request reprint Fragility fractures in chronic kidney disease: an opinion-based approach
    Paul D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Boulevard, Lakewood, CO 80227, USA
    Cleve Clin J Med 76:715-23. 2009
    ..However, even if the patient has osteoporosis, we have little evidence to guide our treatment decisions in cases of advanced chronic kidney disease...
  29. doi request reprint Diagnosis and treatment of osteoporosis in chronic renal disease
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood, CO 80227, USA
    Semin Nephrol 29:144-55. 2009
    ..We need better noninvasive means of discriminating among all these metabolic bone diseases and prospective data to guide us to the use of agents that alter bone remodeling in high-risk patients with more severe CKD...
  30. ncbi request reprint Denosumab: anti-RANKL antibody
    Paul D Miller
    Department of Medicine, University of Colorado Health Sciences Center, Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Lakewood, CO 80227, USA
    Curr Osteoporos Rep 7:18-22. 2009
    ..Denosumab will offer a novel approach to managing postmenopausal osteoporosis, one that should be associated with a high adherence rate and global fracture risk reduction...
  31. doi request reprint Anti-resorptives in the management of osteoporosis
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    Best Pract Res Clin Endocrinol Metab 22:849-68. 2008
    ..This chapter will discuss the data on these effects for each class of anti-resorptive agent...
  32. pmc The role of bone biopsy in patients with chronic renal failure
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, 3190 S Wadsworth Boulevard, 250, Lakewood, CO 80227, USA
    Clin J Am Soc Nephrol 3:S140-50. 2008
    ....
  33. doi request reprint Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Clin Endocrinol Metab 93:3785-93. 2008
    ..The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate...
  34. ncbi request reprint Safety of parathyroid hormone for the treatment of osteoporosis
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Suite 250, Lakewood, CO 80227, USA
    Curr Osteoporos Rep 6:12-6. 2008
    ..This review discusses these issues and provides the author's extensive clinical experience and advice on the use of teriparatide in clinical practice...
  35. ncbi request reprint Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado, USA
    J Bone Miner Res 20:1315-22. 2005
    ..5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year...
  36. ncbi request reprint Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study
    Paul D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO, USA
    Osteoporos Int 17:85-90. 2006
    ..DANCE will provide data on the effectiveness and tolerability of teriparatide therapy in clinical practice that will complement the results of published controlled clinical trials...
  37. ncbi request reprint Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis
    Paul D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO 80227, USA
    Expert Opin Pharmacother 4:2253-8. 2003
    ....
  38. ncbi request reprint Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists
    Paul D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Blvd, Suite 250, Lakewood, CO 80227, USA
    Curr Rheumatol Rep 7:53-60. 2005
    ..This paper deals with the evidence available to understand management of patients with CKD and opinions on what might be a reasonable clinical approach where evidence is currently lacking...
  39. ncbi request reprint Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel
    P D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO 80227, USA
    J Clin Densitom 2:323-42. 1999
    ..We will describe, in practical terms, how bone markers can be appropriately incorporated into clinical practice today...
  40. ncbi request reprint Bone mass measurements
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, 3190 S Wadsworth, Suite 250, Lakewood, CO 80227, USA
    Clin Geriatr Med 19:281-97, vi. 2003
    ....
  41. ncbi request reprint Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis
    Paul Miller
    University of Colorado Health Sciences Center, Lakewood, CO, USA
    South Med J 96:478-85. 2003
    ..Therefore, more weight should be given to data from studies that use the morphometry to assess vertebral fracture incidence...
  42. ncbi request reprint Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis
    P D Miller
    University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, USA
    Osteoporos Int 12:S3-10. 2001
    ..1% between treated and control patients). Bisphosphonate therapy, therefore, appears to be an effective, well-tolerated means of reducing the risk of bone fractures among patients treated with corticosteroids...
  43. doi request reprint The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy
    Marc C Hochberg
    Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Clin Densitom 13:181-9. 2010
    ..61, p=0.0007). These data suggest that 3-mo changes in sCTX levels are associated with 1-yr LS BMD increases in postmenopausal women treated with once-monthly oral ibandronate...
  44. ncbi request reprint An approach to identifying osteopenic women at increased short-term risk of fracture
    Paul D Miller
    Colorado Center for Bone Research, 3190 S Wadsworth Boulevard, Suite 250, Lakewood, CO 80227, USA
    Arch Intern Med 164:1113-20. 2004
    ..We developed a classification algorithm that identifies women with osteopenia (T scores of -2.5 to -1.0) who are at increased risk of fracture within 12 months of peripheral bone density testing...
  45. ncbi request reprint Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review
    P D Miller
    Colorado Center for Bone Research, Lakewood, Colorado, USA
    Clin Exp Rheumatol 26:1125-33. 2008
    ..The good renal tolerability of IV ibandronate in patients with osteoporosis with glomerular filtration rates >30 mL/minute and without renal co-morbid conditions is reassuring...
  46. ncbi request reprint Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Bone Miner Res 22:1832-41. 2007
    ..Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women...
  47. ncbi request reprint Renal safety of intravenous bisphosphonates in the treatment of osteoporosis
    E Michael Lewiecki
    University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
    Expert Opin Drug Saf 6:663-72. 2007
    ..Due to lack of data, no conclusions can be made regarding bisphosphonate safety in patients with intrinsic renal disease or an estimated glomerular filtration rate of < 30 ml/min...
  48. ncbi request reprint Standards for performing DXA in individuals with secondary causes of osteoporosis
    Aliya A Khan
    Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
    J Clin Densitom 9:47-57. 2006
    ..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis...
  49. doi request reprint 2008 Santa Fe Bone Symposium: update on osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 12:135-57. 2009
    ..This is a collection of scientific essays based on presentations and discussions at the 2008 Santa Fe Bone Symposium...
  50. ncbi request reprint Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Bone Miner Res 17:2222-30. 2002
    ..We conclude that low BMD found by peripheral technologies, regardless of the site measured, is associated with at least a twofold increased risk of fracture within 1 year, even at skeletal sites other than the one measured...
  51. pmc The 2002 Canadian bone densitometry recommendations: take-home messages
    Aliya A Khan
    Division of Geriatrics, McMaster University, Hamilton, ON
    CMAJ 167:1141-5. 2002
  52. ncbi request reprint Uses and misuses of quantitative ultrasonography in managing osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    Cleve Clin J Med 73:742-6, 749-52. 2006
    ..As more data become available, however, it may play a larger role. A thorough understanding of the utility and limitations of this test is necessary for using it effectively in clinical practice...
  53. doi request reprint Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 11:313-24. 2008
    ..Presented here are short essays based on the key clinical presentations of the 2007 Santa Fe Bone Symposium...
  54. ncbi request reprint Bone densitometry in asymptomatic primary hyperparathyroidism
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood 80227, USA
    J Bone Miner Res 17:N98-102. 2002
  55. ncbi request reprint Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children
    Aliya A Khan
    Divisions of Endocrinology and Geriatrics, McMaster University, Hamilton, ON, Canada
    J Clin Densitom 7:51-64. 2004
    ..Previously, this group addressed the performance of densitometry in postmenopausal women. This report addresses the use of densitometry in men, premenopausal women, and children with a focus on dual-energy X-ray absorptiometry...
  56. doi request reprint 2009 Santa Fe Bone symposium
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 13:1-9. 2010
    ..Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium...
  57. ncbi request reprint How useful are measures of BMD and bone turnover?
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, CO, USA
    Curr Med Res Opin 21:545-54. 2005
    ..Analyses that have suggested that change in BMD or bone turnover 'explains' little of change in fracture risk with treatment appear to be flawed. Although neither can perfectly predict fracture, they are our current best alternatives...
  58. ncbi request reprint Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 8:143-4. 2005
  59. ncbi request reprint Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA)
    Ethel S Siris
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032 3784, USA
    J Bone Miner Res 19:1215-20. 2004
    ..In a large cohort of postmenopausal women > or =50 years of age, we found the relationship of BMD measured at peripheral sites and subsequent 1-year fracture risk to be similar between women <65 and those > or =65 years of age...
  60. doi request reprint Osteoporosis update from the 2010 santa fe bone symposium
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 14:1-21. 2011
    ..The key messages from each presentation, including the best available medical evidence and potential current and future clinical applications, are provided here...
  61. ncbi request reprint Bone mineral density--clinical use and application
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, 250 Lakewood, CO 80227, USA
    Endocrinol Metab Clin North Am 32:159-79, vii. 2003
    ....
  62. doi request reprint Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw
    Sanford Baim
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Bone Miner Res 24:561-74. 2009
    ..Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated...
  63. ncbi request reprint Defining strategies for improving the identification and management of osteoporosis in the primary care setting
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80212, USA
    Int J Fertil Womens Med 48:261-72. 2003
    ..There is also discussion of the challenges of BMD measurement itself, and the benefit of consideration of other osteoporosis risk factors. Finally, the author provides a set of personal guidelines...
  64. ncbi request reprint New possibilities for diagnosis and treatment of osteoporosis
    P D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood, USA
    Int J Fertil Womens Med 46:215-21. 2001
    ..Both of these compounds have been shown to increase BMD and decrease fracture risk. Monitoring of a patient's response to treatment may be accomplished using serial BMD testing and biomarkers of bone turnover...
  65. ncbi request reprint What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis?
    Paul D Miller
    J Clin Densitom 5:S39-45. 2002
    ..Fourth, peripheral BMD testing performs best when used for postmenopausal women. Further research on all these issues is needed...
  66. ncbi request reprint Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age
    Mark P Ettinger
    Radiant Research and Regional Osteoporosis Center of South Florida, 2081 SE Ocean Boulevard, Stuart, FL, USA
    J Rheumatol 32:1968-74. 2005
    ..We investigated the effect of age on the safety profile of oral daily and intermittent ibandronate, with particular emphasis on the upper gastrointestinal (GI) safety profile of ibandronate...
  67. ncbi request reprint A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    Jean Jacques Body
    Department of Medicine, Institut J Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    J Clin Endocrinol Metab 87:4528-35. 2002
    ..In conclusion, teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate...
  68. ncbi request reprint Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial
    Susan L Greenspan
    University of Pittsburgh Osteoporosis Prevention and Treatment Center, 1110 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA
    Ann Intern Med 136:742-6. 2002
    ..Many elderly female residents of long-term care facilities have osteoporosis and could benefit from intervention to increase bone density...
  69. ncbi request reprint Position Development Conference
    Leon Lenchik
    Division of Radiologic Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    South Med J 96:724-5. 2003
    ..A second Position Development Conference will be held in July 2003 in Cincinnati, OH. For information, visit the ISCD web site: http://www.iscd.org/...
  70. ncbi request reprint Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis
    Paul D Miller
    N Engl J Med 350:189-92; author reply 189-92. 2004
  71. ncbi request reprint Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
    Michael R McClung
    Oregon Osteoporosis Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Arch Intern Med 165:1762-8. 2005
    ..We contrasted the effects of once-daily doses of 20 mug of teriparatide and 10 mg of alendronate sodium on bone mineral density (BMD) and markers of bone turnover...
  72. ncbi request reprint Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
    Charles H Chesnut
    Osteoporosis Research Group, University of Washington, Seattle, WA, USA
    Curr Med Res Opin 21:391-401. 2005
    ..As osteoporosis medications must be effective across different populations, an additional objective of BONE was to investigate and report the effect of oral ibandronate in North American and European women, as described here...
  73. ncbi request reprint Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use
    Anthony B Hodsman
    University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
    Endocr Rev 26:688-703. 2005
    ..At present, concurrent therapy with antiresorptive therapy, particularly bisphosphonates, should be avoided, although sequential therapy with such agents may consolidate the beneficial effects upon the skeleton after PTH is discontinued...
  74. ncbi request reprint Denosumab in postmenopausal women with low bone mineral density
    Michael R McClung
    Providence Portland Medical Center, Portland, Oreg, USA
    N Engl J Med 354:821-31. 2006
    ..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action...
  75. ncbi request reprint Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions
    William D Leslie
    University of Manitoba, Winnipeg, Manitoba, Canada, and McGuire Veterans Affairs Medical Center, Richmond, VA, USA
    J Clin Densitom 9:22-30. 2006
    ..quot; T-scores are preferred and the WHO classification is applicable for postmenopausal women and men age 50 and older. These Official Positions, rationale and evidence are discussed in the following report...
  76. ncbi request reprint New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status
    John H Krege
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Densitom 9:144-9. 2006
    ..Our suggestion is to perform lateral spine imaging concurrently with any assessment of PA spine BMD in patients who, in the opinion of the health care provider, may have vertebral fractures...
  77. ncbi request reprint Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
    Peiqi Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Bone Miner Res 21:1785-90. 2006
    ..Increases in lumbar spine BMD account for 30-41% of the vertebral fracture risk reduction with teriparatide treatment. The remaining fracture risk reduction is caused by improvements in non-BMD determinants of bone strength...
  78. ncbi request reprint Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence
    Neil Binkley
    University of Wisconsin Osteoporosis Clinical Center and Research Program, Madison, Wisconsin, USA
    J Bone Miner Res 20:195-201. 2005
    ..Use of a recalculated young-normal SD for the GE Lunar-adjusted NHANES III database improved diagnostic agreement and is recommended...
  79. ncbi request reprint Osteoporosis and fracture risk in women of different ethnic groups
    Elizabeth Barrett-Connor
    Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA 92093 0607, USA
    J Bone Miner Res 20:185-94. 2005
    ..Weight explained differences in BMD, except among blacks, who had the highest BMD. One SD decrease in BMD predicted a 50% increased fracture risk in each group. Despite similar relative risks, absolute fracture rates differed...
  80. ncbi request reprint Diagnostic agreement at the total hip using different DXA systems and the NHANES III database
    Gary M Kiebzak
    Center for Orthopaedic Research and Education, St Luke s Episcopal Hospital, Houston, TX 77025, USA
    J Clin Densitom 10:132-7. 2007
    ..11 vs 0.32 for lumbar spine (p less than 0.001). Use of the NHANES III standardized database results in good diagnostic agreement at total hip between Prodigy and Delphi...
  81. ncbi request reprint Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis
    Peiqi Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Bone Miner Res 22:1173-80. 2007
    ..Therefore, improvements in trabecular bone microarchitecture may be one of the mechanisms to explain how BMD increases improve bone strength during teriparatide treatment...
  82. ncbi request reprint Letter to the editor
    Marc C Hochberg
    Bone 35:1222-4; author reply 1225-6. 2004
  83. ncbi request reprint DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults
    John J Carey
    Center for Osteoporosis and Metabolic Bone Diseases, Cleveland Clinic, Cleveland, OH, USA
    J Clin Densitom 10:351-8. 2007
    ..Standardization of Z-score definition and method of calculation is indicated. DXA Z-scores should be interpreted with caution in men and women aged 20-50 yr...
  84. ncbi request reprint Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
    Steven T Harris
    University of California, San Francisco, CA 94155 3044, USA
    Curr Med Res Opin 24:237-45. 2008
    ..5 mg oral daily dose. This meta-analysis assessed whether these doses also reduce fracture risk relative to placebo...
  85. ncbi request reprint Bone mineral density thresholds for pharmacological intervention to prevent fractures
    Ethel S Siris
    Metabolic Bone Disease Program, Toni Stabile Osteoporosis Center, Columbia Presbyterian Medical Center, 180 Fort Washington Avenue, New York, NY 10032 3784, USA
    Arch Intern Med 164:1108-12. 2004
    ....
  86. ncbi request reprint Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment
    Wojciech P Olszynski
    Department of Medicine, University of Saskatchewan, Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada
    Clin Ther 26:15-28. 2004
    ..Osteoporosis and fragility fractures in men account for substantial health care expenditures and decreased quality of life...
  87. doi request reprint Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions
    Marc Antoine Krieg
    Lausanne University Hospital, Lausanne, Switzerland
    J Clin Densitom 11:163-87. 2008
    ..The ISCD Official Positions on QUS resulting from this PDC, the rationale for their establishment, and recommendations for further study are presented here...
  88. ncbi request reprint A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate
    Jean Yves Reginster
    Unite d Exploration du Metabolisme de l Os et du Cartilage, CHU Centre Ville, Liege, Belgium
    Osteoporos Int 17:159-66. 2006
    ..Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO...